

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KOTLER KEVIN</u> <hr/> (Last) (First) (Middle) 200 BROADHOLLOW ROAD, SUITE 207 <hr/> (Street) MELVILLE NY 11747 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIODELIVERY SCIENCES INTERNATIONAL INC [BDSI]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/11/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/11/2021		P		150,000	A	\$3.16 ⁽¹⁾⁽²⁾	4,505,689	I	See footnote ⁽³⁾⁽⁴⁾
Common Stock	05/12/2021		P		100,000	A	\$3.24 ⁽²⁾⁽⁵⁾	4,605,689	I	See footnote ⁽³⁾⁽⁴⁾
Common Stock	05/13/2021		P		50,000	A	\$3.25 ⁽²⁾⁽⁶⁾	4,655,689	I	See footnote ⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

1. Name and Address of Reporting Person*
KOTLER KEVIN

 (Last) (First) (Middle)
 200 BROADHOLLOW ROAD, SUITE 207

 (Street)
 MELVILLE NY 11747

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Broadfin Capital, LLC

 (Last) (First) (Middle)
 200 BROADHOLLOW ROAD, SUITE 207

 (Street)
 MELVILLE NY 11747

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Broadfin Healthcare Master Fund Ltd

(Last) (First) (Middle)

20 GENESIS CLOSE ANSBACHER HOUSE,
SECOND FLOOR, P.O. BOX 1344

(Street)

GRAND
CAYMAN KY1- E9
1108

(City)

(State)

(Zip)

Explanation of Responses:

1. On May 11, 2021, the Reporting Person purchased an aggregate of 150,000 shares of the Issuer's Common Stock at a weighted average price of \$3.16 per share. The highest purchase price for the Common Stock was \$3.17 per share and the lowest purchase price was \$3.07 per share.
2. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in these footnotes.
3. 300,000 shares of Common Stock are held in the account of Broadfin Holdings, LLC., a private investment fund, and are deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Holdings, LLC.
4. 4,355,689 shares of Common Stock are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC, and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Broadfin Healthcare Master Fund, Ltd., Broadfin Capital, LLC, and Kevin Kotler affirmatively (i) disclaim beneficial ownership of the reportable securities, (ii) states that this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 ("Section 16") of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, except to the extent of their pecuniary interest therein, and (iii) disclaim being a "group" for purposes of Section 16.
5. On May 12, 2021, the Reporting Person purchased an aggregate of 100,000 shares of the Issuer's Common Stock at a weighted average price of \$3.24 per share. The highest purchase price for the Common Stock was \$3.28 per share and the lowest purchase price was \$3.13 per share.
6. On May 13, 2021, the Reporting Person purchased an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of \$3.25 per share. The highest purchase price for the Common Stock was \$3.27 per share and the lowest purchase price was \$3.24 per share.

Remarks:

BROADFIN CAPITAL, LLC,

By: /s/ Kevin Kotler, Kevin 05/13/2021
Kotler, Managing Member

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.